{
    "clinical_study": {
        "@rank": "4819", 
        "arm_group": [
            {
                "arm_group_label": "rFXIII", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "This trial was conducted in Europe. The aim of this trial was to investigate safety and\n      pharmacokinetics of multiple doses of catridecacog (recombinant factor XIII, rFXIII) in\n      healthy volunteers."
        }, 
        "brief_title": "Safety and Pharmacokinetics of Recombinant Factor XIII Administration in Healthy Volunteers", 
        "completion_date": {
            "#text": "August 2003", 
            "@type": "Actual"
        }, 
        "condition": [
            "Congenital Bleeding Disorder", 
            "Congenital FXIII Deficiency", 
            "Healthy"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Blood Coagulation Disorders", 
                "Hemostatic Disorders", 
                "Hemorrhagic Disorders", 
                "Hemorrhage"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Normal platelet count and clotting parameters\n\n          -  Adequate renal and hepatic function\n\n          -  Negative serum pregnancy test within 21 days prior to enrollment and negative urine\n             pregnancy test on admission to the clinical research unit (if subject female and of\n             child-bearing potential)\n\n          -  Agreement to use a medically accepted form of contraception from the time of\n             enrollment to completion of all follow-up study visits (if subject a sexually active\n             male or female of childbearing potential)\n\n          -  Negative drug and negative alcohol screens\n\n        Exclusion Criteria:\n\n          -  Known antibodies or hypersensitivity to FXIII\n\n          -  Known bleeding or hematologic disorder\n\n          -  Known allergy to yeast\n\n          -  Receipt of blood products within 30 days of screening\n\n          -  Donation of blood within 30 days prior to enrollment\n\n          -  Surgical procedure of any type within 30 days prior to enrollment\n\n          -  History of autoimmune disorders involving autoantibodies, e.g., systemic lupus\n             erythematosus\n\n          -  Treatment with any experimental agent within 30 days of study enrollment"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 2, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01848002", 
            "org_study_id": "F13-1662"
        }, 
        "intervention": [
            {
                "arm_group_label": "rFXIII", 
                "description": "For 5 consecutive days, one daily dose of rFXIII was administered intravenously (IV) to eight subjects in each dose group (10 or 25 U/kg).", 
                "intervention_name": "catridecacog", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "For 5 consecutive days, one daily dose of placebo was administered intravenously (IV) to two subjects in each dose group (10 or 25 U/kg).", 
                "intervention_name": "placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "November 25, 2013", 
        "link": {
            "description": "Clinical Trials at Novo Nordisk", 
            "url": "http://novonordisk-trials.com"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Berkshire", 
                    "country": "United Kingdom", 
                    "zip": "SL1 2 AD"
                }
            }
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Placebo-Controlled, Double-Blind, Multi-dose Study of the Safety and Pharmacokinetics of Recombinant Factor XIII Administration in Healthy Volunteers", 
        "overall_official": {
            "affiliation": "Novo Nordisk A/S", 
            "last_name": "Global Clinical Registry (GCR, 1452)", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "August 2003", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Incidence of adverse events", 
            "safety_issue": "No", 
            "time_frame": "Days 0-33"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01848002"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Incidence of clinically significant changes from baseline in physical examination or laboratory measurements", 
                "safety_issue": "No", 
                "time_frame": "From days -1 through day 33"
            }, 
            {
                "measure": "Incidence of rFXIII antibodies, as measured by ELISA (Enzyme-Linked Immuno Sorbent Assay)", 
                "safety_issue": "No", 
                "time_frame": "From days -1 through day 33"
            }, 
            {
                "measure": "Incidence of yeast antibodies", 
                "safety_issue": "No", 
                "time_frame": "From days -1 through day 33"
            }
        ], 
        "source": "Novo Nordisk A/S", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novo Nordisk A/S", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2003", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}